SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma

This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.

NCT Number	NCT07374549
Lead Sponsor	CSPC Megalith Biopharmaceutical Co.,Ltd.
Conditions	Advanced Urothelial Carcinoma
Enrollment	100 participants
Start Date	2026-06-20
Primary Completion	2028-06-01 (estimated)
Study Completion	2028-12-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-29